Replies to post #398084 on Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

And look. There is more new independent Brilacidin research almost every week. There are no "carrots dangled" here by Ipix.

“There is a scarcity of novel anti-staphylococcal antibiotics hitting the clinic,” explains corresponding author Dr Edward Douglas from the University of Bath.
“In the last 20 years, only two truly novel antibiotic classes have been successfully licensed, the ribosomal targeting oxazolidinone linezolid, and the cell envelope targeting lipopeptide daptomycin."
Similarly, improvements in bioengineering capabilities and our comprehension of how antimicrobial peptides (AMPs) exert their bactericidal activity is facilitating the design of synthetic AMPs such as PLG0206, OP-145, LTX-109 and AMP mimetics such as brilacidin.”
https://www.the-microbiologist.com/news/drugs-pipeline-rife-with-strategies-to-combat-mrsa/939.article

Many people in the world know the Brilacidin name and potential. More every day.
Anja Forche Retweeted
Jorge Amich@JorgeAmich May 5
Brilacidin, a peptide that potentiates caspofungin activity.
Looks like a really promising drug for combinatorial treatments!!
https://twitter.com/AnjaForche